Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-01
DOI
10.1111/joim.13215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients
- (2020) Peter Alping et al. ANNALS OF NEUROLOGY
- Validation of Rapid Magnetic Resonance Myelin Imaging in Multiple Sclerosis
- (2020) Russell Ouellette et al. ANNALS OF NEUROLOGY
- Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
- (2020) Robert T. Naismith et al. CNS DRUGS
- Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
- (2020) Jeremy Chataway et al. LANCET NEUROLOGY
- MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
- (2020) Jaume Sastre-Garriga et al. Nature Reviews Neurology
- Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis
- (2020) Daniel M. Hartung et al. NEUROLOGY
- Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis
- (2020) Andrew P. Robinson et al. Scientific Reports
- Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
- (2020) Tine Iskov Kopp et al. ANNALS OF THE RHEUMATIC DISEASES
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
- (2020) Anna He et al. LANCET NEUROLOGY
- A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- (2020) Edward Fox et al. Multiple Sclerosis Journal
- Remyelination in multiple sclerosis: from basic science to clinical translation
- (2020) Catherine Lubetzki et al. LANCET NEUROLOGY
- Aggressive multiple sclerosis (2): Treatment
- (2020) Georgina Arrambide et al. Multiple Sclerosis Journal
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis
- (2020) Karl E. Carlström et al. Nature Communications
- Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
- (2020) Ludwig Kappos et al. JAMA Neurology
- Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis
- (2020) Andreas Muehler et al. Multiple Sclerosis and Related Disorders
- Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
- (2020) Stanley Cohan et al. Biomedicines
- Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients
- (2020) Allison LM Jordan et al. Multiple Sclerosis Journal
- Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate
- (2020) Daniel Wynn et al. Multiple Sclerosis and Related Disorders
- Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
- (2020) Michael P. Pender et al. JCI Insight
- Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis
- (2019) Lidia Stork et al. Multiple Sclerosis Journal
- Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
- (2019) Hans Lassmann Frontiers in Immunology
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
- (2019) Katharine Harding et al. JAMA Neurology
- Altered human oligodendrocyte heterogeneity in multiple sclerosis
- (2019) Sarah Jäkel et al. NATURE
- Dynamics of oligodendrocyte generation in multiple sclerosis
- (2019) Maggie S. Y. Yeung et al. NATURE
- Out-of-pocket costs are on the rise for commonly prescribed neurologic medications
- (2019) Brian C. Callaghan et al. NEUROLOGY
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
- (2019) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects
- (2019) Luisa Klotz et al. Science Translational Medicine
- Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement
- (2019) Pavan Bhargava et al. Multiple Sclerosis and Related Disorders
- Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
- (2019) Maria Pia Sormani et al. Annals of Clinical and Translational Neurology
- Multiple sclerosis
- (2019) Matteo Pardini et al. CURRENT OPINION IN NEUROLOGY
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
- (2019) Diego Cadavid et al. LANCET NEUROLOGY
- Rituximab treatment for multiple sclerosis
- (2019) Benjamin V Ineichen et al. Multiple Sclerosis Journal
- GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis
- (2019) Edoardo Galli et al. NATURE MEDICINE
- pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
- (2019) David Kremer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
- (2019) Bruce A C Cree et al. LANCET
- Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis
- (2019) L. Scappaticcio et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis
- (2019) D. Baker et al. EUROPEAN JOURNAL OF NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
- (2019) Robert T Naismith et al. Multiple Sclerosis Journal
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
- (2019) Christina Lückel et al. Nature Communications
- T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention
- (2018) Jamie van Langelaar et al. BRAIN
- The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells
- (2018) Joana Machado-Santos et al. BRAIN
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- (2018) Raju Kapoor et al. LANCET NEUROLOGY
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Reassessing B cell contributions in multiple sclerosis
- (2018) Rui Li et al. NATURE IMMUNOLOGY
- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
- (2018) Alexander Rae-Grant et al. NEUROLOGY
- Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis
- (2018) Jeremy Chataway et al. NEUROLOGY
- IL-1β enables CNS access to CCR2himonocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells
- (2018) Alexandre Paré et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Alemtuzumab as Treatment for Multiple Sclerosis
- (2018) Serafeim Katsavos et al. Cold Spring Harbor Perspectives in Medicine
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study
- (2018) Julian Gold et al. Multiple Sclerosis and Related Disorders
- Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
- (2018) Ivan Jelcic et al. CELL
- Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab
- (2018) Jennifer Petrillo et al. JOURNAL OF NEURO-OPHTHALMOLOGY
- Neurofilaments as biomarkers in neurological disorders
- (2018) Michael Khalil et al. Nature Reviews Neurology
- Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
- (2018) Tanuja Chitnis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deciding on the Best Multiple Sclerosis Therapy
- (2018) Joseph R. Berger et al. JAMA Neurology
- Intrathecal treatment trial of rituximab in progressive MS
- (2018) Joakim Bergman et al. NEUROLOGY
- Multiple sclerosis
- (2018) Massimo Filippi et al. Nature Reviews Disease Primers
- Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
- (2017) Ari J Green et al. LANCET
- Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Vincent Meininger et al. LANCET NEUROLOGY
- Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
- (2017) Mark A Agius et al. Multiple Sclerosis Journal
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
- (2017) Paolo A. Muraro et al. Nature Reviews Neurology
- Alemtuzumab CARE-MS I 5-year follow-up
- (2017) Eva Havrdova et al. NEUROLOGY
- Autologous hematopoietic stem cell transplantation in multiple sclerosis
- (2017) Maria Pia Sormani et al. NEUROLOGY
- Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012
- (2017) Sarah Burkill et al. NEUROLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis
- (2017) Luanne M. Metz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
- (2017) Mark A Agius et al. Multiple Sclerosis Journal
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
- (2016) Assunta Dal-Bianco et al. ACTA NEUROPATHOLOGICA
- The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
- (2016) Lukas Haider et al. BRAIN
- Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study
- (2016) P. S. Sørensen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
- (2016) Eva Havrdová et al. JOURNAL OF NEUROLOGY
- Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
- (2016) Caryl J. Schwartzbach et al. JOURNAL OF NEUROLOGY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
- (2016) Ludwig Kappos et al. LANCET NEUROLOGY
- A genetic basis for multiple sclerosis severity: Red herring or real?
- (2016) Vilija G. Jokubaitis et al. MOLECULAR AND CELLULAR PROBES
- ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis
- (2016) Samia J Khoury et al. Multiple Sclerosis Journal
- High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
- (2016) Karen Schreiber et al. Multiple Sclerosis Journal
- Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis
- (2016) Tomas Olsson et al. Nature Reviews Neurology
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
- (2016) Douglas L. Arnold et al. NEUROLOGY
- ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis
- (2016) Samia J Khoury et al. Multiple Sclerosis Journal
- High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial
- (2016) Karen Schreiber et al. Multiple Sclerosis Journal
- Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
- (2016) Mika Komori et al. Annals of Clinical and Translational Neurology
- Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation
- (2015) Catherine Larochelle et al. ANNALS OF NEUROLOGY
- Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque
- (2015) Josa M. Frischer et al. ANNALS OF NEUROLOGY
- ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
- (2015) Robert C. Sergott et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies
- (2015) Jesus Lovera et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Pathological mechanisms in progressive multiple sclerosis
- (2015) Don H Mahad et al. LANCET NEUROLOGY
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis
- (2015) Yonghao Cao et al. Science Translational Medicine
- Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis
- (2015) Daniel M. Harrison et al. JAMA Neurology
- Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis
- (2015) Jeffrey Cohen et al. JAMA Neurology
- GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis
- (2015) Jerry S. Wolinsky et al. Multiple Sclerosis and Related Disorders
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- Cardiotoxicity of Mitoxantrone Treatment in a German Cohort of 639 Multiple Sclerosis Patients
- (2014) Vinzenz Fleischer et al. Journal of Clinical Neurology
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
- (2014) T. L. Vollmer et al. JOURNAL OF NEUROLOGY
- Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
- (2014) Ludwig Kappos et al. LANCET NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
- (2014) Thomas P Leist et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Therapy-related acute leukaemia with mitoxantrone: Four years on, what is the risk and can it be limited?
- (2014) Richard Ellis et al. Multiple Sclerosis Journal
- Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
- (2014) Feng Mei et al. NATURE MEDICINE
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
- (2013) Maria Pia Sormani et al. LANCET NEUROLOGY
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort
- (2013) Tomas Olsson et al. Multiple Sclerosis Journal
- Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study
- (2013) Christian Wolf et al. PLoS One
- The mechanism of action of glatiramer acetate in multiple sclerosis and beyond
- (2012) Rina Aharoni AUTOIMMUNITY REVIEWS
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
- (2012) David H Miller et al. LANCET NEUROLOGY
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Communication between pathogenic T cells and myeloid cells in neuroinflammatory disease
- (2012) Laura Codarri et al. TRENDS IN IMMUNOLOGY
- Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
- (2011) Owain W. Howell et al. BRAIN
- Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
- (2011) S Cook et al. Multiple Sclerosis Journal
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
- (2010) Roberta Magliozzi et al. ANNALS OF NEUROLOGY
- The changing demographic pattern of multiple sclerosis epidemiology
- (2010) Nils Koch-Henriksen et al. LANCET NEUROLOGY
- A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis
- (2010) Timothy L Vollmer et al. Multiple Sclerosis Journal
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
- (2009) Richard K Burt et al. LANCET NEUROLOGY
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood—brain barrier disruption in multiple sclerosis
- (2009) Bibiana Bielekova et al. Multiple Sclerosis Journal
- Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
- (2008) Hideki Garren et al. ANNALS OF NEUROLOGY
- Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial
- (2008) Clarissa E. Vergunst et al. ARTHRITIS AND RHEUMATISM
- Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies
- (2008) Ralf A Linker et al. Expert Review of Neurotherapeutics
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
- (2008) Benjamin M Segal et al. LANCET NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation